Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $0.31 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Xenon Pharmaceuticals Trading Down 3.4 %

NASDAQ:XENE opened at $38.37 on Tuesday. The company has a market capitalization of $2.93 billion, a P/E ratio of -13.61 and a beta of 1.20. Xenon Pharmaceuticals has a 12 month low of $35.53 and a 12 month high of $50.99. The business’s 50-day moving average is $39.45 and its 200 day moving average is $40.37.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on XENE shares. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $57.38.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. This trade represents a 34.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 57,492 shares of company stock worth $2,334,969. Company insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.